- Beaufort Securities has reiterated its positive ‘speculative buy’ recommendation on Tiziana Life Sciences [LON:TILS] after the company announced that it had entered into an agreement with Novimmune for an exclusive license to clinically develop and commercialise Foralumab.

The broker said: “The deal marks an important milestone in Tiziana’s journey to become an established player in biotechnology.

“The oncology and immunology focussed company has significantly broadened its horizon and is on way to become a clinical stage company shortly.

“The wide range application and potential of Foralumab, puts the company in a supreme position to unlock value in the multi-billion dollar markets.â€

At 2:04pm: [LON:TILS] Tiziana Life Sciences Plc Ord 3p share price was 0p at 51.5p

Story provided by